AUROPHARMA

Eugia Pharma Unit II received "Official Action Indicated" (OAI) classification from the USFDA after a November inspection with nine observations. The company sees no material impact but faces ongoing regulatory scrutiny with Unit III also under OAI status and a May 2024 warning letter.